$CDLX

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdlx_form8-kx2026q2xex991.htm EX-99.1 Document Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Con

Original reporting
Published Aug 5, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CDLX
Neutral
medium confidence
Mentioned
$CDLX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDLXNeutralMed
01

Why it matters

Traders can update near-term expectations using the disclosed Q3 guidance bands and assess whether the margin improvement narrative offsets continued YoY declines in revenue, billings, users, and cash flow.

02

Market read

Fresh quarterly metrics plus explicit Q3 guidance create a tradable setup into and during the earnings webcast.

03

What to watch

MQUs fell 17% YoY and ACPU declined, so the key question is whether Q3 guidance implies stabilization in unit economics or continued top-line shrinkage.

Relevance 7/10Novelty 8/10Timing: after-hours/earnings call today, Aug 5, 2026 at 5:00 PM ET

Background

This is an SEC Form 8-K with Exhibit 99.1 covering Cardlytics’ Q2 2026 financial results and Q3 2026 guidance ranges.

Company-level read

Ticker impact

$CDLXNeutralMedium confidence
Context

Cardlytics reported Q2 2026 results and provided Q3 2026 guidance ranges for Billings, Revenue, Adjusted Contribution, and Adjusted EBITDA.

Expected impact

Likely modest volatility around the earnings call and any market reaction to the guidance ranges versus expectations, with downside risk if investors focus on worsening net loss and cash burn.

Evidence & confidence

The filing discloses fresh quarterly datapoints (revenue, billings, net loss, FCF) plus explicit Q3 guidance ranges, which can drive repricing even without a beat/raise narrative.

Market effects

Signals ongoing pressure on purchase-intelligence monetization (declining billings, users) while emphasizing margin improvement and self-sustainability efforts.

No specific regional read-through beyond US and UK platform operations mentioned.

Limited global impact; primarily a US-listed ad-tech/purchase-intelligence name with UK exposure.

Counterpoint

Investors may discount the “within guidance” framing and focus on worsening net loss, operating cash outflow, and free cash flow deterioration versus the prior year.

Key entities

  • Cardlytics, Inc.

    Purchase intelligence platform reporting Q2 2026 results and issuing Q3 2026 guidance ranges.

  • Amit Gupta

    CEO quoted on execution translating into results and being within guidance across key metrics.

  • David Evans

    CFO quoted on sequential growth and self-sustainability plan.

Related articles

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$HMNMed

Horace Mann Educators Q2 Earnings Call Highlights

Horace Mann (NYSE:HMN) reported Q2 call highlights. Management said auto frequency and severity trends were favorable and liability losses mid-single digits. It cut its full-year catastrophe-loss assumption to about $75M from $90M, while lowering total net investment income outlook to $465M-$475M. Revenue rose 8% YoY; life sales +20%.

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.